DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Market Assessment

Get the full story of a disease with insights powered by primary market research, real world data, and disease-area expertise directly from within the Market Assessment Insights Platform

 

Request a Demo

 

Epidemiology

Gain insight into epidemiology covering 170+ indications and biomarkers, 45 countries, and 3,500+ subpopulations
Know More

Forecasting

Understand disease-specific markets and therapies, including sales forecasts by branded or generic/biosimilar drug, class, and type
Know More

Disease Management

Discover current and predicted treatment protocols, prescribing behaviors, and the detailed patient journey, for a wide range of indications
Know More

DRG’s Market Assessment solutions illuminate brand usage across different lines of therapy, identifying opportunities for increased market positions and highlighting unmet needs that can translate into commercial opportunities, enabling you to maximize market share.

Explore our Market Assessment Solutions

China In-Depth

Assess commercial opportunities and optimize your strategy with comprehensive China pharma market data and insights for ten key indications.

Learn More

Unmet Need

Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity

Learn more

Patient Profiler

Identify potential commercial opportunities within key patient segments using U.S. claims data and electronic health records

Learn more

Emerging Therapies

Track performance, prescriber and non-prescriber insights on uptake of key new drugs and the impact on market dynamics in three waves post-launch

Learn more

Biosimilars Insights

Size the opportunity in this lucrative market and evaluate the disruptive effects biosimilars are having on the pharma industry

Learn more